PBYI vs. TELO, TSVT, ACIU, HOWL, XERS, FHTX, VNDA, NBTX, AEON, and ALDX
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Telomir Pharmaceuticals (TELO), 2seventy bio (TSVT), AC Immune (ACIU), Werewolf Therapeutics (HOWL), Xeris Biopharma (XERS), Foghorn Therapeutics (FHTX), Vanda Pharmaceuticals (VNDA), Nanobiotix (NBTX), AEON Biopharma (AEON), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology (NASDAQ:PBYI) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.
Puma Biotechnology received 534 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.
61.3% of Puma Biotechnology shares are owned by institutional investors. 22.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Puma Biotechnology has a net margin of 9.16% compared to Telomir Pharmaceuticals' net margin of 0.00%. Puma Biotechnology's return on equity of 58.21% beat Telomir Pharmaceuticals' return on equity.
In the previous week, Puma Biotechnology had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Puma Biotechnology and 1 mentions for Telomir Pharmaceuticals. Puma Biotechnology's average media sentiment score of 0.53 beat Telomir Pharmaceuticals' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the media.
Puma Biotechnology currently has a consensus price target of $7.00, suggesting a potential upside of 34.62%. Given Puma Biotechnology's higher possible upside, equities research analysts clearly believe Puma Biotechnology is more favorable than Telomir Pharmaceuticals.
Puma Biotechnology has higher revenue and earnings than Telomir Pharmaceuticals.
Summary
Puma Biotechnology beats Telomir Pharmaceuticals on 12 of the 12 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology Competitors List
Related Companies and Tools
